CCL2 and Nephropathy: Although further study is warranted to assess how much the anti-inflammatory properties of SGLT2 inhibitor contributes kidney protection, an exploratory mediation analysis of a cardiovascular outcome trial reported that the effect of canagliflozin on urinary MCP-1 partly mediated reduction in kidney injury morecule-1, a marker of kidney damage, in patients with type 2 diabetes and CKD [19].